December 30, 2025
1 min read
The CAVIAR trial evaluated safety and efficacy of the PCSK9 inhibitor alirocumab for prevention of cardiac allograft vasculopathy after heart transplantation.
Read Healio’s in-depth coverage of the CAVIAR trial.
CAVIAR included 114 patients who within 6 months after heart transplantation were randomly assigned to alirocumab (Praluent, Sanofi/Regeneron) plus rosuvastatin or rosuvastatin alone.
At 1 year, LDL levels decreased significantly in the alirocumab group, whereas there was no change in the rosuvastatin-only group.
However, the primary endpoint of change in coronary plaque volume from baseline to 1 year on serial intravascular ultrasound was not significantly different between the alirocumab and rosuvastatin-only groups.
Results of CAVIAR were presented at the American Heart Association Scientific Sessions and simultaneously published in Circulation.
Read Healio’s complete coverage of AHA 2025 here.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
